Juniper Pharma (JNP) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results
May 6, 2015 7:01 AM EDTBOSTON, May 6, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), today announced financial results for the three-month period ended March 31, 2015. First quarter financial highlights include:
Total revenues were $8.3 million, an increase of 19% as compared to $7.0 million in the first quarter of 2014; Product revenues increased 41% year-over-year, enabled by the return of normalized CRINONE® (progesterone gel) shipments to Merck Serono in the fourth quarter of 2014; Service revenues grew 9% year-over-year and 42% from the fourth quarter of 2014, on a local currency basis; Operating profit... More